Showing papers in "Cancer Treatment Reviews in 2010"

TL;DR: The present contribution reports childhood cancer incidence and survival rates as well as time trends and geographical variation based on the databases of population-based cancer registries which joined forces in cooperative projects such as Automated Childhood Cancer Information System (ACCIS) and EUROCARE.

TL;DR: An overview about secondary plant products in general is given and mechanisms of preventive and therapeutic effects of cruciferae, particular the brassica family and their famous member broccoli are focused on.

TL;DR: The results of the present study suggest that an "aggressive curettage" reduces the recurrence rate in a disease whose aggressiveness is not easy to predict.

TL;DR: The aim of this review is to summarize the most relevant knowledge on triple-negative breast cancer in terms of molecular features, pathogenesis, clinical characteristics, current treatments and the new therapeutic options that include the use of platinum compounds, EGFR antagonists, antiangiogenics and PARP inhibitors.

TL;DR: Catumaxomab is the first trAb and the first drug worldwide to be approved specifically for the treatment of MA and is in clinical trials in a number of other indications including ovarian and gastric cancer.

TL;DR: A systematic review of the literature on the health effects of exercise during cancer rehabilitation and evaluating the methodological rigour of studies in this area to date is presented in this article, where the authors identified relevant studies through a systematic search of PubMed and Embase to April 2009.

TL;DR: The most recent data taken together swing the pendulum towards an immunologic aberration in LCH, and patients with multisystem (MS) disease with organ dysfunction, particularly those refractory to front line therapy, and those with multiple reactivations of disease associated with significant permanent sequelae represent the greatest challenge.

TL;DR: A summary of the basic mechanistic role of APE1 in DNA repair and redox regulation is provided and preclinical and clinical data that confirm APe1 as a valid anticancer drug target are highlighted.

TL;DR: It appears increasingly likely that delayed, dysregulated responses to 'common' infectious agents play a major part in the conversion of pre-leukaemic clones into overt precursor B cell ALL, the most common form of childhood leukaemia.

TL;DR: Emerging clinical data with dasatinib support experimental observations, with preliminary phase 1 and 2 data demonstrating activity, both as a single agent and as combination therapy, in a range of solid tumors.

TL;DR: A review of the literature revealed 32 relevant studies that investigated the concordance of the hormone receptors (ER and/or PR) and HER2 after NAC with or without trastuzumab.

TL;DR: The results of women with hematological malignancies treated with systemic therapies during the course of pregnancy show Lymphoma, acute leukemia and chronic myeloid leukemia were the most commonly treated.

TL;DR: Current knowledge on mechanism-based in vitro and in vivo studies on the chemopreventive and chemotherapeutic potential of resveratrol in liver cancer, present in grapes, berries, peanuts as well as red wine, are examined.

TL;DR: The updated knowledge on TNBC is summarized, with emphasis on its current treatment and on the new therapeutic options under development, to represent a major challenge for breast oncologist.

TL;DR: Neuroblastoma is the first pediatric cancer for which monoclonal-antibody-based immunotherapy has been shown to be effective, particularly for metastatic osteomedullary disease, and efforts are under way to refine and enhance antibody-based Immunotherapy and to determine its optimal use.

TL;DR: Intravesical chemotherapy with either Mitomycin C or Epirubicin would be an option for those patients failing or who are unsuitable for BCG therapy, and there is no conclusive evidence that one agent is superior in terms of overall survival.

TL;DR: With the addition of targeted therapy, especially anti-angiogenic and anti-Her2 therapy, and a better understanding of the biology of the disease, perhaps a sense of optimism should indeed suppress the nihilism commonly associated with this disease.

TL;DR: Current evidences show similar quality of life profile between oral and intravenous treatments, although anticancer oral therapy seems to be more convenient in terms of administration and reduced time lost for work or other activities.

TL;DR: Data is summarized on several FoxM1 inhibitors especially "chemopreventive agents" and these agents could be useful for targeted inactivation ofFoxM1, which indeed could become a novel approach for the prevention and/or treatment of human cancer.

TL;DR: This review focuses on the rationale for arc therapy, descriptions of the modern arc techniques that are currently clinically available, and highlights some distinguishing features of arc therapies, such as dose distributions, treatment times, and imaging capabilities.

TL;DR: The molecular bases that have led to the clinical application of the detection for genetic impairments of the epidermal growth factor receptor pathway are reported and a potential algorithm is provided as a guide in the choice of the best treatment for patients with adenocarcinoma.

TL;DR: The responses in patients with CML are durable whereas durable responses in other diseases are rare, and DLI has taken a backseat given the development of new drugs to treat some hematological diseases.

TL;DR: Male breast cancer accounts for around 1% of all breast cancer cases, but the incidence has increased over the past 25 years, and the rarity of this entity precludes prospective randomized clinical trials.

TL;DR: A multidisciplinary consensus conference convened to review recent progress in basic and clinical research, assess gaps in current knowledge and prioritize recommendations to advance research over the next 5 years addressed three topics: advancing understanding of metastasis prevention in the context of bone pathophysiology; developing therapeutic approaches to prevent metastasis and defining strategies to prevent cancer therapy-induced bone loss.

TL;DR: Preliminary data from phase 1/2 trials, including tumor responses and bone-specific activity in patients with prostate or breast cancer, demonstrate that SRC inhibitors have potential in the clinical setting.

TL;DR: A review gives an overview over many different potential therapeutic targets for treatment of these childhood sarcomas, including receptor tyrosine kinases, intracellular signaling molecules, cell cycle and apoptosis regulators, proteasome, hsp90, histone deacetylases, angiogenesis regulators and sarcoma specific fusion proteins.

TL;DR: It appears that BRAF mutations may play a strong negative prognostic role and only a slight role in resistance to anti-EGFR Abs, and the role of B-RAF mutations, mutually exclusive with KRAS mutations, in predicting resistance toAnti- EGFR mAbs is not yet consolidated.

TL;DR: The use of weekly paclitaxel regimens is recommended for the treatment of locally advanced/metastatic breast cancer and the observed survival benefit does not seem to stem from an increased potency of the drug with weekly regimens.

TL;DR: It is suggested that PDT be considered as a good candidate for adjuvant treatment in post-resected malignant metastatic melanoma and primary consideration must be given to organelle-specific destruction in melanoma specifically targeting the melanosomes.

TL;DR: Pre-clinical data suggest that PARP inhibitors may potentiate the effects of radiotherapy in several tumour types, namely lung, colorectal, head and neck, glioma, cervix and prostate cancers, and clinical trials to assess the toxicity and potential benefit of combining radiotherapy with PARP inhibition are needed.